1980 One day, a Japanese cardiologist who was studying thrombolytic drugs had to see Dr. Yang Hang. It suddenly occurred to him that natto is not fermented by cellulose. Fibrin is the most stubborn part of the thrombus, so at 2: 30 in the afternoon, I have to go to see Dr. Yang Hang to add the substance extracted from natto to the artificial thrombus.
Originally, the results were to be seen the next day, but at 5: 30, through an accidental inspection, a miracle happened. Thrombosis actually dissolved 2 cm, but it usually takes nearly two days to dissolve 2 cm in the experiment of urokinase dissolving thrombus, which means that the speed of natto fermentation dissolving thrombus is 19 times that of urokinase. Therefore, this powerful thrombolytic substance of natto was named nattokinase (NK), which was the famous "2: 30 pm" experiment in the history of thrombolytic drug research that shocked the world. The Japanese Institute of Life Sciences and the Center for Cardiovascular and Cerebrovascular Diseases of Yonsei University in Seoul, South Korea jointly studied the effect of nattokinase on hypertension. The conclusion of this study is: "In short, nattokinase can reduce systolic and diastolic blood pressure. This result shows that increasing the intake of nattokinase may play an important role in the prevention and treatment of hypertension. " The research report was included in the international authoritative journal SCI (Japanese Hypertension Society, Vol.3 1 No.8, ISSN09 16_9636 in August 2008).
Japan Institute of Biological Sciences and TNMC & Mumbai, India; Bayer Hospital conducted a comprehensive clinical study on the treatment of acute stroke patients with nattokinase+low molecular weight heparin+anticoagulant drugs. The experimental results show that oral nattokinase+low molecular weight heparin+antiplatelet aggregation drugs have significant therapeutic effect on acute ischemic stroke. The research report was also published by the international authoritative journal SCI (JPN Pharmacology Journal, Volume 32, No.7, 2004 TNMC &; Department of Neurosurgery, BYLNair Hospital).
The Japanese Institute of Life Sciences of Japan Co., Ltd. and the Center for the Treatment and Research of Difficult Diseases of Santa Mariana Medical University of Japan jointly conducted a study on the inhibition of platelet coagulation and the prevention of thrombosis by nattokinase. The conclusion of this study is that nattokinase can not only dissolve thrombus, but also inhibit platelet aggregation and prevent thrombosis. The results of this experiment were published at the Japanese Pharmaceutical Society in March 2003.
In addition, the Japanese Institute of Life Sciences also conducted studies on blood morphology after nattokinase intake, finger blood flow changes in retinal vein occlusion test, and the antagonistic effect of vitamin K2 in natto on warfarin. According to Dr. Kogasawara, from a medical point of view, the thrombolytic mechanism of nattokinase is as follows: nattokinase stimulates vascular endothelial cells to produce tissue plasminogen activator (t-PA), which activates plasminogen into plasmin, dissolves fibrin and directly dissolves thrombus; At the same time, prourokinase in human body is activated into urokinase, and urokinase and t-PA jointly activate plasminogen to dissolve thrombus.
It can be seen that nattokinase can not only directly dissolve thrombus, but also activate and enhance the human body's own thrombolytic ability, thus playing a lasting and stable thrombolytic role. Moreover, Dr. Kogasawara said: "Nattokinase only dissolves fibrin, the main substance of thrombosis, and does not hydrolyze plasma fibrinogen, so it will not cause the risk of bleeding." This is generally lacking in clinical thrombolytic drugs. In addition, further clinical studies have found that nattokinase also has obvious antihypertensive and platelet aggregation inhibition effects. NattoKinase (NK) is a kind of protein extracted from food natto or fermented by Bacillus natto. Its molecular weight is much smaller than that of UK, SK and tPA, and it can be absorbed by intestinal tract. The thrombolytic characteristics of NK in vitro and in vivo were also determined by experiments. At the same time, it is concluded that NK's thrombolytic activity in vivo is four times that of fibrinolytic enzyme, and it has a rapid and long-lasting effect in vivo, and can also activate tPA in vivo to make it mild. Patients at risk of myocardial infarction need to be injected with 300,000 units of urokinase once, and 50 grams of natto contains 800,000 units of urokinase for thrombolysis. (See the report of foreign firms, each gram of wet natto is equivalent to about 1600 urokinase unit. )
The research center for the treatment of difficult diseases of Santa Mariana Medical University in Japan and the Japan Institute of Life Sciences found that nattokinase can inhibit platelet coagulation and help prevent hypertension and arteriosclerosis.
According to the nihon keizai shimbun, the researchers asked the subjects to eat the cultured extract of nattokinase and then tested their blood. They found that the coagulation of platelets was inhibited after eating this extract for 6 hours. The researchers concluded that nattokinase has the function of dissolving thrombus and making blood flow smooth.
Therefore, nattokinase has become a new oral thrombolytic drug (second generation thrombolytic drug), which plays an active role in the prevention and treatment of cardiovascular and cerebrovascular embolism and embolic Alzheimer's disease. International standard content identifier
20 10 12.20, China National Center for Medical Education and Development was invited by Japan Nattokinase Association and Japan Institute of Life Sciences, the patent owner of nattokinase, to hold a press conference in Beijing Media Center, and issued a statement: Japan Institute of Life Sciences is the largest nattokinase raw material manufacturer in Japan and even the whole world, and it is the only one with the nattokinase production patent granted by Japan Patent Office (patent No.3881. The nattokinase developed in this study is produced by fermentation of Bacillus natto culture solution and extracted and purified by special technology and process. The high-purity nattokinase product made of this material has the function of dissolving thrombus and is a high-tech product in the field of modern biology. Its safety and effectiveness have been verified by medical clinic and fully recognized by Japan Nattokinase Association. In addition, the standard unit of nattokinase products formulated by Japan's official health and nutrition food association is "FU", not "IU".
The difference between FU and FU/g
The international standard unit of nattokinase is "FU", which refers to the nattokinase content of each nattokinase product; "FU/g" refers to the content of nattokinase per gram of natto raw material, and there is a difference between them.